Tag:

Five Prime Therapeutics

Latest Headlines

FivePrime scores $495M cancer deal with Human Genome Sciences

March 17, 2011

Fresh off the approval of lupus drug Benlysta, red-hot Human Genome Sciences ( $HGSI ) is paying $50 million up front and up to $445 million in milestones to gain development rights for FivePrime's

THE LIBRARY: WEBINAR

Getting the most PoC data in Phase I cancer studies

| June 12, 11am ET/ 8am PT

The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!

MORE ITEMS

EVENTS

MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
What's your BIO?June 18-21, 2012 — Boston, MA

MORE EVENTS

Press Releases

Featured Jobs

Entry Level Process Engineer and Lead Process Engineer
Foster Wheeler Biokinetics - San Francisco, CA
Sr. Director/Executive Director of Operations, Inflammation and Immunology CRD Job
Celgene Corporation - Tokyo, Ja, US
Food Development Scientist Job
Yoh - Park Ridge, NJ, USA
Aseptic Operations Manager
DPT Labs - Lakewood, NJ
Regulatory Scientist Assistant III (Senior) Job
Yoh - Kenilworth, NJ, USA

Five Prime Therapeutics

Latest Headlines

Latest Headlines

FivePrime scores $495M cancer deal with Human Genome Sciences

THE LIBRARY: WEBINAR

EVENTS

Press Releases

Featured Jobs

A publication of FierceMarkets

The FierceMarkets Network:

Telecom

Healthcare

Government

Energy

Life Sciences

Enterprise IT

Finance

Five Prime Therapeutics

Latest Headlines

Latest Headlines

FivePrime scores $495M cancer deal with Human Genome Sciences

Related Tags